中国の医薬品業界見通し：2008〜2023年

Abstract

This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains.

Over 220 pages full of analysis, graphs, tables and charts - available to you today.

If you are interested in pharmaceutical business in China, you cannot afford to be without this report by visiongain' s leading authority on developing pharmaceutical markets.

• The growth of pharmaceutical markets in the developing nations has the potential to offset the slowdown of sales growth in developed markets of North America, Europe and Japan.
• Visiongain predicts that China will exhibit very strong pharma sales growth from 2008-2023. Rapid economic growth and a vast, currently under-served population, will drive that expansion. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors.

Visiongain' s Chinese Pharmaceutical Outlook 2008-2023 examines the exciting Chinese pharmaceutical market and industrial sector critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, surveying of key opinion leaders, SWOT analyses and discussion of qualitative factors. Societal, political, economic and commercial issues are covered. The result is a comprehensive market-based report with detailed analysis and informed opinion. This original 220+ page study contains 57 tables and 47 figures. We invite you to examine the table of contents included here.

In particular, visiongain' s Chinese Pharmaceutical Outlook 2008-2023 concentrates on the following themes:

• A forecast of the global pharmaceutical market from 2007-2023, with key issues discussed
• Forecasts of sales revenues and growth rates for Chinese pharmaceutical sales from 2007-2023, including key market segments such as Rx, OTC, domestic and foreign sales - all with comprehensive discussion
• Forecasts of sales for leading therapeutic areas and pharma products
• Revenue forecasts for clinical outsourcing in China and relevant discussion
• Revenue forecasts for contract manufacturing in China and relevant discussion
• Drivers and opportunities in the Chinese pharmaceutical sector
• Restraints and threats in that market and industry
• Discussion of key domestic players and important therapeutic areas, including biotechnology, drug development and joint ventures
• Discussion of regulatory, societal and economic issues

Why you should buy this report:

• To receive a comprehensive analysis of the Chinese pharma market and industry from 2007-2023, with both quantitative and qualitative aspects covered
• To discover predicted revenues, sales growth rates and other key metrics for the Chinese pharma sector from 2006-2023
• To determine the forces that influence pharmaceutical sales and related developments in China:
• Competitive characteristics of the market and industry
• Regulatory, technological, societal and political issues
• Drivers and restraints
• Strengths, weaknesses, opportunities and threats
• Expert opinion from China, as obtained by visiongain
• To find out where the Chinese market is heading - both commercially and technologically - including regulatory issues
• To determine key activities of leading companies
• To receive a comprehensive discussion of healthcare provision in China, both public and private.

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for over 80% of revenues for prescription drugs worldwide. However, there is great concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are striving to raise their profiles in the developing markets of Asia, Latin America and Eastern/Central Europe. Principal amongst those developing markets is the emergent demographic and economic colossus of China.

Growth of the pharmaceutical markets in developing nations will clearly surpass that of the established markets throughout the foreseeable future. That situation will provide one of the greatest opportunities ever available to the international pharmaceutical industry. Those strongly growing national economies drive the reform and broadening of healthcare systems, with increasing sales in all healthcare sectors. Improvements in both the quality and reach of these healthcare provisions will drive the sales of branded and generic drugs in particular. This report will help you to understand those developments and opportunities.

Other benefits to you when you order this report:

• Full searchable report when you buy the company or corporate editions
• Copies can be easily printed for offline reading

Table of Contents

1 Executive Summary: Chinese Pharmaceutical Outlook 2008-2023

• 1.1 Introduction to the Report
• 1.2 Research Methods and Content
• 1.3 Growth of the Chinese Pharma Market from 2007-2023
• 1.4 Cautious Optimism for Chinese Pharma

2 Introduction: Expansion into Developing Markets - Principally China

• 2.1 The World Pharmaceutical Market Continues to Grow, But Faces Mounting Challenges
• 2.2 The Continuing Success of the Pharmaceutical Industry is Dependent upon Important Drivers and Restraints
  • 2.2.1 Drivers on the Global Pharmaceutical Market 2007-2020
  • 2.2.2 The Market Will Also Face Considerable Restraints During the Foreseeable Future
• 2.3 Companies Are Gradually Changing Their Strategic Focus to Overcome Challenges in the Worldwide Market
• 2.4 Current Pressures on Industry - Blockbuster Business Model Under the Spotlight
• 2.5 R&D Strategy is Crucial to Success
• 2.6 Greater Regulatory Co-operation is Possible Internationally
• 2.7 China Was the Ninth Largest World Pharmaceutical Market in 2006 and Is Set to Climb Much Higher in the Rankings in Coming Years
• 2.8 North America, Europe and Japan Continue to Dominate the World Pharmaceutical Market, But Sales in the Developing Markets Are Increasing More Rapidly
• 2.9 High Growth in the Developing Pharmaceutical Markets
  • 2.9.1 Sales Growth in Developing Nations is Outstripping that of the Overall World Market and Individual Developed Nations
  • 2.9.2 Improving Access to Modern Healthcare is a Principal Driver of Growth in Developing Nations
• 2.10 China is the Most Exciting Prospect for the Pharmaceutical Industry at the Moment
  • 2.10.1 China is a Potential Economic Leader
  • 2.10.2 China' s Total Pharmaceutical Sales are Still Far Behind Those of the US and Japan
  • 2.10.3 Strategies for Market Entry and Consolidation are Vital for International Companies
• 2.11 WTO Agreements Affect Pharmaceutical Developments in Emerging Markets
  • 2.11.1 The Principal Pharmaceutical Markets Remain the Leading Developed Nations But Developing Nations Are Increasingly Tempting
  • 2.11.2 Background to the WTO and TRIPS
  • 2.11.3 Lack of Patent Protection Was Rife in Developing Nations Before TRIPS
• 2.12 Pharmaceutical Companies Will Jostle Vigorously for Position in Developing Markets Such as China
  • 2.12.1 Further International Expansion Will Occur in Pharma from 2008 to 2020 with China Being a Principal Beneficiary
  • 2.12.2 Expansion into Developing National Markets Will Help to Reinvigorate the Pharmaceutical Industry
• 2.13 The Chinese Pharma Industry will be a Principal Beneficiary of Globalisation

3 The Chinese Pharmaceutical Market: its Key Players, Principal Therapeutic Areas, Market Drivers and Restraints

• 3.1 SWOT Analysis of the Chinese Pharmaceutical Market from 2008-2020 Shows Both Major Opportunities and Challenges Ahead
• 3.2 Growth in National and Personal Prosperity Will Raise Demand for Pharmaceutical Products in China
  • 3.2.1 List of Principal Drivers of the Chinese Pharmaceutical Market from 2008-2020
  • 3.2.2 China Attracts all the Leading Pharma Companies and has a Growing Domestic Pharma Industry
  • 3.2.3 Demographic Changes are a Major Driver of Pharmaceutical Sales in China
  • 3.2.4 Patent Protection and GMP Compliance are also Highly Important to Chinese Pharma Market Development
  • 3.2.5 Rationalisation of the Supply Chain will be a Key Factor
  • 3.2.6 Modern Pharmaceutical Products Increasing in Usage with Corresponding Decline in Chinese Traditional Medicine
• 3.3 Remaining Concerns over the Commercial Environment in China will act as a Restraint to Market Growth
  • 3.3.1 List of Principal Restraints on the Chinese Pharmaceutical Market from 2008-2020
  • 3.3.2 More Effective Regulatory Process and Greater IP Protection Help but Progress Required
  • 3.3.3 Lower Prices Reduce Profit Margins
  • 3.3.4 New Civil Court for IP Infringement Announced in 2006
  • 3.3.5 China' s Healthcare Provision Requires Major Progress in the Years Ahead
  • 3.3.6 Expanding Healthcare Provision Occurring Gradually Since 1990s
• 3.4 Both the Chinese Economy and Its Pharmaceutical Market Benefit from Having the World' s Largest Population and Labour Force
  • 3.4.1 World' s Largest Population Gives China Vast Potential Pharmaceutical Demand in Coming Years
  • 3.4.2 China has Already become a Major Force in Manufacturing with Economic Growth and Important Demographic Changes Occurring at a Relentless Pace
  • 3.4.3 Expansion and Improvement of Education and Training in China Will Increasingly Benefit the Pharmaceutical Sector
• 3.5 China' s Overall Economic Output May Rise to $4 Trillion by 2020
  • 3.5.1 Output Reached $1.6 Trillion in 2005
  • 3.5.2 China Rising Fast in International Economic League Tables
  • 3.5.3 Emphasis on Increasing Personal Income and Consumption
  • 3.5.4 Increasing Range of Economic Activities in China
  • 3.5.5 Further Opening of Chinese Economy Will Spur Growth in the Years Ahead
• 3.6 Greater Expectations for Healthcare and Increasing Resources to Pay for Treatments Will Further Drive the Chinese Pharmaceutical Market
  • 3.6.1 Rising Living Standards Drive Growth of Pharma Industry with both Foreign and Domestic Companies Benefiting
  • 3.6.2 An Expanding Professional Class in China with High Demand for Modern Pharmaceuticals
  • 3.6.3 Marked Disparities Exist Between the Cities and the Rural Areas: Relative Poverty Is a Continuing Problem for China, With Implications for the Pharmaceutical Market
• 3.7 The State Food and Drug Administration is the Main Pharmaceutical Regulator in China
  • 3.7.1 Reorganisation and Consolidation of Pharma Regulation
  • 3.7.2 The State Food and Drug Administration (SFDA)
  • 3.7.3 Submission of NDAs and Approval Process in China
  • 3.7.4 Policy of Requiring Local Clinical Trials an Impediment to the Pharma Market in China
  • 3.7.5 Other Regulatory Functions
  • 3.7.6 Combined Centre for Drug and Medical Device Approvals by SFDA
  • 3.7.7 New Regulations for Certifying Imported Bulk Pharmaceuticals
• 3.8 Western Medicine is Gradually Superseding Traditional Medications in China - Important Progress Being Made but Formidable Challenges Remain
  • 3.8.1 Low Average Per Capita Healthcare Spending at Present but Increasingly Strong Market for Modern Prescription Drugs and OTC Products in China
  • 3.8.2 Generic Drugs are a Major Component of the Chinese Pharma Market
  • 3.8.3 Jiangsu YangZijiang Was the Market Leader in 2006 with International Pharmaceutical Leaders Also Performing Well
  • 3.8.4 Domestic Companies Achieving Impressive Sales Growth in the Chinese Market but International Companies Playing Important Role Through Subsidiaries
  • 3.8.5 The Cephalosporin Class Led the Chinese Market in 2006
  • 3.8.6 Pricing and Reimbursement Issues
  • 3.8.7 Marketing and Advertisement
• 3.9 Pfizer Expanding its Presence in China, Aligning Itself More Closely With the Chinese Healthcare Authorities and Other Stakeholders
  • 3.9.1 Pfizer is Foremost Amongst International Companies Operating in China
  • 3.9.2 Pfizer' s Alliances in China are Significant
  • 3.9.3 Pfizer has a Broad Vision for Competing in the Chinese Market
• 3.10 Novartis is also a Leading Pharmaceutical Investor in China
  • 3.10.1 Novartis Recently Made Significant Inward Investment
  • 3.10.2 New Plant in Jiangsu Province
• 3.11 Novo Nordisk Recently Announced Expansion of Production in China - Great Opportunities for Specialist Pharma Companies
  • 3.11.1 China Will Become a Leading Market for Diabetes Treatments - Novo Nordisk is Very Well Placed in that Market
  • 3.11.2 New Productions Facilities in Tianjing
• 3.12 State AIDS Prevention and Treatment Policy in China is Indicative of Greater State Involvement in Healthcare with Opportunities for all Stakeholders
  • 3.12.1 Intensive AIDS Prevention and Treatment Programme Announced in February 2008
  • 3.12.2 Chinese Science at Forefront of AIDS/HIV Research in Developing World
  • 3.12.3 Important Opportunities for Both Leading and Specialised Companies in the Chinese Anti-Retroviral Market
• 3.13 Chronic Diseases Associated with Lifestyle are Increasing Rapidly in China
  • 3.13.1 China Now a Leading Nation for Obesity
  • 3.13.2 Disease Awareness Campaigns for Chronic "Western" Diseases
  • 3.13.3 Opportunities for Pharmaceutical Companies to Alleviate These Problems

4 The Chinese Pharmaceutical Market is Expanding Rapidly - Detailed Market Forecasts from 2007 to 2020

• 4.1 The Chinese Pharmaceutical Market Will Grow Significantly Faster than the Global Pharmaceutical Market from 2007-2020
  • 4.1.1 Chinese Pharmaceutical Market Will Expand to over $30bn by Early Next Decade with Strong Growth Continuing to 2020
  • 4.1.2 Chinese Pharma Market Surpassing Global and Developed Markets in Annual Sales Growth - How This Trend Will Continue
  • 4.1.3 China' s World Pharma Market Share Will Continue to Increase from 2007-2020
  • 4.1.4 WTO and to TRIPS Issues Remain Important for the Chinese Pharma Market
  • 4.1.5 Pharma Sales Growth Will Remain Strong Despite Inevitable Slowing of Chinese Economic Growth and Healthcare Expansion in Future Years
  • 4.1.6 Investment in Drug Development by Chinese Companies a High Priority with State Measures Encouraging Progress
  • 4.1.7 Inefficiencies and Disparities in Chinese Healthcare Provision Currently Hamper Growth but Much Hope for Improvements
• 4.2 Prescription Drug Sales Will Continue to Drive the Chinese Market from 2007-2020
  • 4.2.1 Sales of Prescription Drugs in China Set to Exceed $50bn by Late Next Decade with a CAGR over 15%
  • 4.2.2 Relative Market Shares for Prescription and OTC Products in China from 2007-2020
  • 4.2.3 OTC Sector Boosted by Trend for Self Medication, Especially for Patients Without Health Cover
  • 4.2.4 Drivers of the Chinese OTC Market Segment
  • 4.2.5 Multinational Companies and their Subsidiaries Making Good Progress in OTC Sector
  • 4.2.6 Community Pharmacies and Online Sales Driving Growth
  • 4.2.7 Disease Awareness Campaigns and Increasing Number of Outlets also Main Drivers of OTC Segment in China
• 4.3 Currently Generic Drugs Dominate the Chinese Prescription Drug Market but Original Patented Brands Will Make Inroads
  • 4.3.1 Strong Growth in both Branded and Generic Sectors from 2007-2020
  • 4.3.2 Competitive Factors Influencing Sales of Domestic Generics in China
  • 4.3.3 Large Supply of Generic Drugs by Local Producers Provides Domestic Industry with a Major Advantage
  • 4.3.4 Effects of Generics on Pricing Structures in China
  • 4.3.5 Tightening of Regulations for Generic Drug Marketing in China
  • 4.3.6 Gradual Change in Balance of Sales Contributed by Original Branded and Generic Products in the Chinese Pharma Market from 2007-2020
  • 4.3.7 Lack of Bioequivalence Certification for Domestic Generics is a Commercial Weakness that Needs to be Rectified
  • 4.3.8 Economic Forces Protect International Companies from Generic Competition in the Chinese Market at Present
• 4.4 Domestic Companies Retain Leadership in the Chinese Market but Multinational Pharma is Catching Up
  • 4.4.1 Visiongain Forecasts Strong Sales for Both Domestic and Foreign Pharma Companies in China from 2007-2020
  • 4.4.2 Gradual Change in Balance of Sales Contributed by Domestic and Foreign Companies in the Chinese Pharma Market from 2007-2020
  • 4.4.3 Chinese Pharmaceutical Industry Lags Behind Other Major Domestic Industries as well as the Indian Pharma Sector
  • 4.4.4 Domestic Producers Can Affect Pricing Structures in Chinese Pharma Market
  • 4.4.5 Supply Chain Advantages for Domestic Producers
  • 4.4.6 Most Pharma Companies Located in the Dynamic Eastern and South China Zones
• 4.5 Forecasts for Leading Therapeutic Classes in the Chinese Pharmaceutical Market from 2007-2013
  • 4.5.1 Leading Drug Classes in China will Show Marked Growth from 2007-2023
  • 4.5.2 Growing Opportunities in Many Areas Including both Traditional Ailments and Modern Western-Style Diseases
• 4.6 Forecasts for Leading Companies in the Chinese Pharmaceutical Market from 2007-2013
  • 4.6.1 Leading Companies both Domestic and Foreign Will Exhibit Strong Sales Growth from 2007-2023
  • 4.6.2 Bayer - A Potential Leader of the Chinese Pharma Market?
• 4.7 The Pharmaceutical Market in China will be Driven by the Especially Strong Performance of the Chinese Economy from 2007 to 2020
  • 4.7.1 Historic Economic Progress Makes China Ready for a Healthcare Revolution
  • 4.7.2 Greater Inclusion in Public Healthcare Coverage will Constitute a Win-Win for Healthcare Stakeholders in China
• 4.8 Political and Economic Reform Has Led to a Burgeoning Private Sector - International Pharmaceutical Companies Have Already Established Themselves in China
  • 4.8.1 Great Reforms in China Since 1978
  • 4.8.2 Improvement of Private Industry and Financial Sector Remains a Challenge
  • 4.8.3 Visiongain is Confident of Increasing Foreign Involvement in Chinese Pharma Sector - a Win-Win Situation for Companies and Other Stakeholders
• 4.9 Mandatory Pricing Reductions Cause the International Pharma Industry Concern
  • 4.9.1 The National Reform and Development Commission
  • 4.9.2 Recent Price Cuts in Key Classes in China
  • 4.9.3 Reform of NRDC Policies and Processes May Bring Some Relief for Industry
  • 4.9.4 The Centralised Tendering System Has an Effect on Pharmaceutical Revenues
• 4.10 Pharmaceuticals are a Major Source of Revenue Generation in Chinese Hospital System - Pharma Companies Need to Focus on those Powerful Buyers
  • 4.10.1 Hospital Pharmacies are Principal Dispensers of Drugs in China
  • 4.10.2 National Reimbursement Bulletin Guides Specific Formularies
  • 4.10.3 Anti-Corruption Campaign in 2006 had Implications for Prescribing Practices
  • 4.10.4 Proposals to Limit Drug Mark-Ups in Hospitals and Some Price Rises at Source
  • 4.10.5 Funding Situation in Hospitals will Improve - Healthcare Stakeholders will Benefit
• 4.11 Developments in Intellectual Property in China Remain Vitally Important to the Global Pharma Industry
  • 4.11.1 Counterfeiting and Related Patent Incursions are Still Problematical in China
  • 4.11.2 Protection of Intellectual Property is Gradually Improving in China but Serious Concerns Remain
  • 4.11.3 Many Sales of Counterfeits and Illegal Generics Occur via the Internet
  • 4.11.4 Pfizer Recently Initiated an Anti-Counterfeiting Programme in Shanghai
  • 4.11.5 The Chinese Authorities Are Tightening Regulations and Enforcement
• 4.12 Pharma Distribution Channels in China are Evolving
  • 4.12.1 Key Players Control Distribution
  • 4.12.2 Sole Authorized Agents
  • 4.12.3 The Market Network System
  • 4.12.4 A More Direct and Independent System
  • 4.12.5 E-Business and Retailing Chain Stores Show Potential
• 4.13 Visiongain Concludes that China is the Largest and Most Attractive Developing Market for Pharmaceuticals

5 Domestic Companies with Strong Promise for the Future Especially in Original Drug Development

• 5.1 Original R&D Investment Lacking to Date but High Expectations from Chinese Government for Future
  • 5.1.1 Visiongain Believes that China Will Make Important Progress in Developing Novel Drugs for International Markets
  • 5.1.2 Relatively Low Investment in R&D is Still a Major Limitation
  • 5.1.3 Bio-scientific Knowledge and Skills Increasing Rapidly
  • 5.1.4 Pre-clinical and Clinical Trial Activities Emerging Rapidly
  • 5.1.5 The Chinese Pharmaceutical Industry and the Domestic Market have Noteworthy Characteristics
  • 5.1.6 Xiangxue Pharmaceuticals to Extend into UK
• 5.2 Significant Changes to Regulatory Processes Occurred During 2007
  • 5.2.1 Changes to the Administration of Drug Regulation
  • 5.2.2 New Drug Registration Procedures Now Far More Discerning
  • 5.2.3 Improved Transparency and Speed of Regulatory Processes
  • 5.2.4 Special Approval Procedures for APIs, Biologicals and Some Chemical Agents
• 5.3 Harbin Pharmaceutical Group
  • 5.3.1 Harbin Pharmaceutical Group is a Leading Antimicrobial Producer in China
  • 5.3.2 Antimicrobial Agents - a Speciality
  • 5.3.3 Foreign Investment in Harbin
  • 5.3.4 Novel R&D Activities
  • 5.3.5 Active Pharmaceutical Ingredients (APIs)
  • 5.3.6 Branded Products
  • 5.3.7 Generic Products
• 5.4 Shijiazhuang Pharma Group
  • 5.4.1 Shijiazhuang Pharma Group is a Leading State-Owned Pharma Company
  • 5.4.2 Original R&D by Shijiazhuang Pharma Group
  • 5.4.3 Key Competencies of Shijiazhuang Pharma Group
  • 5.4.4 Subsidiaries and Affiliations
• 5.5 Sinovac Biotech Ltd
  • 5.5.1 Sinovac Biotech is a Prominent Chinese Biotechnology Company and a Leader in Vaccines
  • 5.5.2 Sinovac Reported Impressive Sales and Profit Growth in 2006
  • 5.5.3 Bilive - the First Combined Inactivated Hepatitis A&B Vaccine
  • 5.5.4 Healive - an Inactivated Hepatitis A Vaccine
  • 5.5.5 Anflu - a Split Influenza Vaccine
  • 5.5.6 Pipeline Developments in Sinovac Biotech
  • 5.5.7 Sinovac Announced $9.75m Private Placement in Early 2008
• 5.6 WuXi PharmaTech
  • 5.6.1 WuXi PharmaTech is an Exciting Pharma R&D Outsourcing Company
  • 5.6.2 WuXi PharmaTech - a Leading International Pharma Services Company of the Future?
• 5.7 Interview with the Director of an Expanding Chinese Pharmaceutical Company
  • 5.7.1 The Greatest Challenges facing the Chinese Pharma Sector
  • 5.7.2 Growth Potential of Chinese Pharma Market
  • 5.7.3 China and IP Protection
  • 5.7.4 Development of Novel Pharmaceuticals in China
  • 5.7.5 Pricing Trends in the Chinese Market - 2008 Onwards
  • 5.7.6 Composition of Pharma Sales in China
  • 5.7.7 Public Healthcare Spending from 2008 Onwards
  • 5.7.8 Multinational Companies vs. Domestic Companies
  • 5.7.9 Development of the Wholesale and Distribution System
  • 5.7.10 Governmental Support for Chinese Pharma
  • 5.7.11 Inward Investment in the Chinese Pharma Sector
• 5.8 China Has Expanding Role in Biologics and Biogenerics (Biosimilars)
  • 5.8.1 China Has Established Biogenerics Companies
  • 5.8.2 Emerging FDA and EMEA Policy for Biogenerics Creates Great Opportunities for Indian and Chinese Biotechnological Companies
  • 5.8.3 China Will Compete Internationally in Biogenerics and Eventually Original Biologics

6 The Clinical Trials Outsourcing Market in China

• 6.1 The Clinical Trials Markets in China Will Increase Steadily from 2007-2023
  • 6.1.1 China Has Growing Presence in Clinical Outsourcing but Lags Behind India
  • 6.1.2 Chinese Clinical Outsourcing will Expand Steadily from 2007 to 2023
  • 6.1.3 Lack of Harmonisation a Challenge
• 6.2 Many Factors are Considered When Deciding Clinical Trial Location but Quality of Data Should Be Paramount
  • 6.2.1 Both China and India are Attractive Locations for Clinical Trials
  • 6.2.2 The Quality Issue and Other Operational Factors
• 6.3 China Faces Real Challenges to Establish Itself in the Clinical Trials Market
  • 6.3.1 China' s Large Treatment-Naïve Population Is Attracting Investment but Healthcare Infrastructure Needs to Be Enhanced
  • 6.3.2 Multinational CROs have also Moved into China
  • 6.3.3 Rapid Growth of the Pharmaceutical Market Will Drive Clinical Research in China
  • 6.3.4 Enforcement of Intellectual Property Law Is the Most Pressing Issue for China
  • 6.3.5 Lack of Clinical Trial Standardisation Will Also Inhibit Growth
  • 6.3.6 China Will Take Some Time to Fulfil its Potential in this Sector
• 6.4 The Drive for Patient Recruitment has Pushed Clinical Trials East
  • 6.4.1 Speed and Cost in Clinical Development
  • 6.4.2 Advantages of Outsourcing Clinical Trials in China
  • 6.4.3 Disadvantages of Outsourcing Clinical Trials in China
  • 6.4.4 Costs of Clinical Testing in China will Not Remain Low Forever
  • 6.4.5 Exciting Prospects in China: Where Optimism and Caution Meet

7 Outsourced Pharmaceutical Manufacturing in China

• 7.1 Low-Cost Manufacturing in China is Very Attractive to International Pharmaceutical Companies
  • 7.1.1 Expanding Contract Pharma Markets in China - APIs in Particular
  • 7.1.2 Outsourcing to China as a Tactical Decision
  • 7.1.3 FDA Approval and GMP in China
• 7.2 Drivers and Restraints on Outsourced Pharma Manufacturing in China
  • 7.2.1 TRIPs and Other Regulations Affect China in Particular
  • 7.2.2 Not all International Companies Believe that Outsourced Pharma Manufacture in China is Desirable
  • 7.2.3 How International GMP Standards Will Affect the Chinese Pharma Industry
• 7.3 The Importance of APIs to Chinese Sector: Opportunities and Challenges
  • 7.3.1 Increasing Competition and Commoditisation - Especially in Bulk Pharma Manufacturing
  • 7.3.2 Biotechnological Capacity in China from the Present Looking Forward
  • 7.3.3 Overcoming the Challenges of this Transitional Period in Pharma Manufacturing
• 7.4 China' s Role in API Production and Export Will Grow Significantly in the Years Ahead
  • 7.4.1 Chinese Exports of APIs Will Exceed $15bn by 2013 with Further Growth Predicted
  • 7.4.2 China Will Prosper in API Production at the Expense of Traditional European Producers
  • 7.4.3 While China is an Expanding Producer of APIs, India is a Serious Rival - Who Will Win During Coming Years?
  • 7.4.4 European API Producers Set to Lose Market Share to China
  • 7.4.5 Shares by Class and Costs by Volume
  • 7.4.6 Geographical Distribution of Chinese Pharma Exports
  • 7.4.7 China is Also an Important Producer of Pharmaceutical Intermediaries

8 Pharmaceutical Joint Ventures

• 8.1 International Joint Ventures in Chinese Healthcare
  • 8.1.1 An Important Driver of Pharmaceutical Market Growth
  • 8.1.2 Incentives to Foreign Investment in the Chinese Pharma Sector
  • 8.1.3 Characteristics of Healthcare Joint Ventures (JVs)
  • 8.1.4 Joint Ventures an Established Strategy
• 8.2 Important Healthcare Policy Regulates Joint Ventures
  • 8.2.1 Entry Criteria for Companies
  • 8.2.2 Chinese-Foreign Equity Joint Venture Law
  • 8.2.3 Technology Transfer and its Regulation
  • 8.2.4 Economic Zones and Chinese Industrial Policy
• 8.3 State Owned Enterprises (SOEs)
  • 8.3.1 SOEs are a Salient Characteristic of the Chinese Pharma Sector
  • 8.3.2 Healthcare (Hospital) Joint Ventures in China
  • 8.3.3 Provisional Regulations on the Administration of Healthcare Joint Ventures
  • 8.3.4 MPOH and MOFTEC Requirements Affect Market Participants
• 8.4 Research and Development
  • 8.4.1 China is Making Only Gradual Progress in Mobilising its Public Sector Science and Engineering
  • 8.4.2 ROI in State Research Remains Low
  • 8.4.3 IP Issues as Restraints to Progress in Basic Healthcare Science

9 Conclusions

• 9.1 The Chinese Pharmaceutical Market Will Expand to over $30bn by Early Next Decade with Strong Growth Continuing to 2020
• 9.2 Sales of Prescription Drugs in China Set to Exceed $50bn by Late Next Decade with a CAGR over 15%
• 9.3 Strong Growth in both Branded and Generic Sectors from 2007-2020
• 9.4 Visiongain Forecasts Strong Sales for Both Domestic and Foreign Pharma Companies in China from 2007-2020
• 9.5 There Will be a Gradual Change in Balance of Sales Contributed by Domestic and Foreign Companies in the Chinese Pharma Market from 2007-2020
• 9.6 The Leading Drug Classes in China will Show Marked Growth from 2007-2023
• 9.7 Demographic Changes a Major Driver of Pharmaceutical Sales
• 9.8 Visiongain Concludes that China is the Largest and Most Attractive Developing Market for Pharmaceuticals

Appendices

• Appendix A: The Chinese Pharma Regulatory System
• Appendix B: Healthcare Insurance in China
• Appendix C: Drug Pricing
• Appendix D: About Visiongain
• Appendix E: Visiongain Report Evaluation Form

List of Tables

• Table 1.1 World Market and China: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
• Table 2.1 Total Sales ($bn) of the World Pharmaceutical Market, 2000-2006
• Table 2.2 Forecast Sales ($bn) of the World Pharmaceutical Market, 2007-2013
• Table 2.3 Forecast Sales ($bn) of the World Pharmaceutical Market, 2014-2020
• Table 2.4 Major Drugs Losing Patent Expiry in Near Future
• Table 2.5 Top 20 Ranking Nations in the Global Pharmaceutical Market, 2006
• Table 2.6 World Pharmaceutical Sales ($bn) by Region, 2005
• Table 2.7 Total Sales ($bn), Growth (%) and Market Share (%) for Leading Developing Markets, 2005
• Table 2.8 Combined Total Sales ($bn), Growth (%) and Market Share (%) for Leading Developing Markets by Region, 2005
• Table 2.9 The 10 Most Populous Countries - 2005 and 2030 Compared
• Table 3.1 A SWOT Analysis for the Chinese Pharmaceutical Market, 2008-2023
• Table 3.2 China: Fundamental Demographics and Healthcare Economics, 2006
• Table 3.3 Chinese Sales of Leading Companies in the Chinese Pharmaceutical Market by Sales ($m), 2006
• Table 3.4 Leading Domestic Companies in China by Sales ($m), 2006
• Table 3.5 Fastest Growing Domestic Companies in China by Sales ($m), 2006
• Table 3.6 Leading Therapy Classes China, 2006
• Table 3.7 Fastest Growing Therapy Classes in China by Sales ($m), 2006
• Table 3.8 Leading Pharmaceutical Agents in China by Sales ($m), 2006
• Table 4.1 Total Pharmaceutical Sales ($bn) in China and the World Compared, 2007-2013
• Table 4.2 World Market and China: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
• Table 4.3 Total Pharmaceutical Sales ($bn) in China and the World Compared, 2014-2020
• Table 4.4 CAGR (%) for Pharmaceutical Sales in China and the Total World Market, 2007-2020
• Table 4.5 China' s Share (%) of Total World Pharma Market Sales, 2007-2013
• Table 4.6 China' s Share (%) of Total World Pharma Market Sales, 2014-2020
• Table 4.7 Total Sales ($bn) of Prescription and OTC Medicines in China, 2007-2013
• Table 4.8 Total Sales ($bn) of Prescription and OTC Medicines in China, 2014-2020
• Table 4.9 Prescription and OTC Medicines: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
• Table 4.10 CAGR (%) for Total Sales of Prescription and OTC Medicines in China 2007-2020
• Table 4.11 Market Shares (%) Held by Prescription and OTC Medicines in China, 2007-2013
• Table 4.12 Market Shares (%) Held by Prescription and OTC Medicines in China, 2014-2020
• Table 4.13 Total Sales ($bn) of Original Branded and Generic Prescription Drugs in China, 2007-2013
• Table 4.14 Total Sales ($bn) of Original Branded and Generic Prescription Drugs in China, 2014-2020
• Table 4.15 Branded and Generic Prescription Drugs: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
• Table 4.16 CAGR (%) for Total Sales of Original Branded and Generic Prescription Drugs in China, 2014-2020
• Table 4.17 Shares (%) of the Prescription Drug Market Held by Original Patented and Generic Prescription Drugs in China, 2007-2013
• Table 4.18 Shares (%) of the Prescription Drug Market Held by Original Patented and Generic Prescription Drugs in China, 2014-2020
• Table 4.19 Total Sales ($bn) of Domestic Pharma Companies and Foreign Pharma in China, 2007-2013
• Table 4.20 Total Sales ($bn) of Domestic Pharma Companies and Foreign Pharma in China, 2014-2020
• Table 4.21 Domestic Pharma Companies and Foreign Pharma: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
• Table 4.22 CAGR (%) for Total Sales of Domestic Pharma Companies and Foreign Pharma in China, 2007-2020
• Table 4.23 Shares (%) of Chinese Pharma Market Held by Domestic Companies and Foreign Companies, 2007-2013
• Table 4.24 Shares (%) of Chinese Pharma Market Held by Domestic Companies and Foreign Companies, 2014-2020
• Table 4.25 Sales ($m) of Leading Therapy Classes in China, 2007-2013
• Table 4.26 Sales ($m) of Leading Therapy Classes in China, 2007-2013 (Continued)
• Table 4.27 CAGR (%) for Sales of Leading Therapy Classes in China, 2007-2013
• Table 4.28 Leading Therapy Classes: Long Range Sales Forecasts ($m) with CAGR (%), 2007-2023
• Table 4.29 Chinese Sales ($m) of Leading Companies in the Chinese Pharmaceutical Market, 2007-2013
• Table 4.30 Chinese Sales ($m) of Leading Companies in the Chinese Pharmaceutical Market, 2007-2013 (Continued)
• Table 4.31 CAGR (%) for Chinese Sales of Leading Companies in the Chinese Pharmaceutical Market, 2007-2013
• Table 4.32 Leading Companies: Long Range Sales Forecasts ($m) with CAGR (%), 2007-2023
• Table 6.1 Revenues ($bn) for Chinese Clinical Trials Sector, 2007-2013
• Table 6.2 Revenues ($bn) for Chinese Clinical Trials Sector, 2014-2020
• Table 6.3 Clinical Trials in China: Long Range Revenue Forecasts ($bn) with CAGR (%), 2007-2023
• Table 6.4 Disease Prevalence (m) in China, 2006
• Table 7.1 Revenues ($bn) for Chinese API Exports, 2007-2013
• Table 7.2 Revenues ($bn) for Chinese API Exports, 2014-2020
• Table 7.3 Chinese API Exports: Long Range Revenue Forecasts ($bn) with CAGR (%), 2007-2023
• Table 7.4 Leading Chinese Exported APIs, 2005

List of Figures

• Figure 1.1 Total Pharmaceutical Sales ($bn) in China, 2007-2020
• Figure 2.1 Total Sales ($bn) of the World Pharmaceutical Market, 2000-2006
• Figure 2.2 Forecast Sales ($bn) of the World Pharmaceutical Market, 2007-2020
• Figure 2.3 The Drug Development Process is Long, Complex and Costly
• Figure 3.1 Breakdown (%) of the Chinese Market ($bn) by Conventional Prescription Drugs, OTC Products and Traditional Chinese Medicines, 2005
• Figure 4.1 Total Pharmaceutical Sales ($bn) in China and the World Compared, 2007-2013
• Figure 4.2 Total Pharmaceutical Sales ($bn) in China, 2007-2013
• Figure 4.3 Total Pharmaceutical Sales ($bn) in China and the World Compared, 2014-2020
• Figure 4.4 Total Pharmaceutical Sales ($bn) in China, 2014-2020
• Figure 4.5 CAGR (%) for Pharmaceutical Sales in China and the Total World Market, 2007-2020
• Figure 4.6 China' s Share (%) of Total World Pharma Market Sales, 2007-2013
• Figure 4.7 China' s Share of the World Pharmaceutical Market in 2007
• Figure 4.8 China' s Share of the World Pharmaceutical Market in 2010
• Figure 4.9 Total Pharmaceutical Sales ($bn) in China and the World Compared, 2007-2013
• Figure 4.10 Growth of Total Sales in China and World Market Compared, 2007-2013
• Figure 4.11 Growth in Pharmaceutical Sales in China, 2007-2013
• Figure 4.12 Rate of Growth (%) of Percentage Market Share for China in the Global Pharmaceutical Market, 2007-2013
• Figure 4.13 China' s Share (%) of Total World Pharma Market Sales, 2014-2020
• Figure 4.14 China' s Share of the World Pharmaceutical Market in 2014
• Figure 4.15 China' s Share of the World Pharmaceutical Market in 2020
• Figure 4.16 Total Pharmaceutical Sales ($bn) in China and the World Compared, 2014-2020
• Figure 4.17 Growth of Total Sales China and World Market Compared, 2014-2020
• Figure 4.18 Growth in Pharmaceutical Sales in China, 2014-2020
• Figure 4.19 Rate of Growth (%) of Percentage Market Share for China in the Global Pharmaceutical Market, 2014-2020
• Figure 4.20 Total Sales ($bn) of Prescription and OTC Medicines in China, 2007-2013
• Figure 4.21 Total Sales ($bn) of Prescription and OTC Medicines in China, 2014-2020
• Figure 4.22 CAGR (%) for Total Sales of Prescription and OTC Medicines in China 2007-2020
• Figure 4.23 Market Shares (%) Held by Prescription and OTC Medicines in China, 2007-2013
• Figure 4.24 Market Shares (%) Held by Prescription and OTC Medicines in China, 2014-2020
• Figure 4.25 Total Sales ($bn) of Original Branded and Generic Prescription Drugs in China, 2007-2013
• Figure 4.26 Total Sales ($bn) of Original Branded and Generic Prescription Drugs in China, 2014-2020
• Figure 4.27 Total Sales of Original Branded and Generic Prescription Drugs in China CAGR (%), 2014-2020
• Figure 4.28 Shares (%) of the Prescription Drug Market Held by Original Patented and Generic Prescription Drugs in China, 2007-2013
• Figure 4.29 Shares (%) of the Prescription Drug Market Held by Original Patented and Generic Prescription Drugs in China, 2014-2020
• Figure 4.30 Total Sales ($bn) of Domestic Pharma Companies and Foreign Pharma in China, 2007-2013
• Figure 4.31 Total Sales ($bn) of Domestic Pharma Companies and Foreign Pharma in China, 2014-2020
• Figure 4.32 Total CAGR (%) for Total Sales of Domestic Pharma Companies and Foreign Pharma in China, 2007-2020
• Figure 4.33 Shares (%) of Chinese Pharma Market Held by Domestic Companies and Foreign Companies, 2007-2013
• Figure 4.34 Shares (%) of Chinese Pharma Market Held by Domestic Companies and Foreign Companies, 2014-2020
• Figure 4.35 Sales ($m) of Leading Therapy Classes in China, 2006-2013
• Figure 4.36 Sales ($m) of Leading Therapy Classes in China, 2006-2013 (Continued)
• Figure 4.37 Chinese Sales ($m) of Leading Companies in the Chinese Pharmaceutical Market, 2006-2013
• Figure 4.38 Chinese Sales ($m) of Leading Companies in the Chinese Pharmaceutical Market, 2006-2013 (Continued)
• Figure 6.1 Revenues ($bn) for Chinese Clinical Trials Sector, 2007-2020
• Figure 6.2 Factors Affecting Clinical Trial Location
• Figure 7.1 Revenues ($bn) for Chinese API Exports, 2007-2020
• Figure 7.2 Market Share (%) of the Chinese API Market by Class, 2005
• Figure 7.3 Global Distribution of Chinese API Exports, 2005

Companies Mentioned in this Report

• Anhui Anke Biotechnology
• Anhui BBCA Biochemical
• AppTec Laboratory Services
• AstraZeneca
• Aventis Pharma
• Bayer AG
• Bayer Schering Pharma Asia Pacific
• Beijing SL Pharmaceutical
• Beijing Tiantan Biological Products
• Beijing Tri-Prime Genetic Engineering
• Bristol Myers Squibb
• Changchun ChangSheng Gene
• Changchun Institute of Biological Products
• Chengdu Rongsheng Pharmaceuticals
• China National Biotec Corp (CBNC)
• China Pharmaceutical Group
• Cipla
• Citic Capital
• Danish Centre for Clinical and Basic Research
• Dr. Reddy' s Laboratories
• Eli Lilly
• Fresenius
• GlaxoSmithKline
• Guangxi Beisheng Pharmaceuticals
• Hainan Sanyang Pharma
• Hangzhou Jiuyuan Gene Engineering
• Harbin Pharmaceutical Group
• Hebei Zhongrun Pharmaceutical Co
• HLJ Haerbin Pharma
• Hualan Biological Engineering
• Huawei
• Jiangsu YangZijiang Js. LYG Hengrui
• Johnson & Johnson
• Jx.Nanchang Yufeng
• Lenovo
• M.S.D.-Hangzhou
• MDS Pharma Services
• Microsoft
• Motorola
• NCPC Genetech Biotechnology
• Shanghai Institute of Biological Products
• Northeast General Pharmaceutical Factory
• Novartis
• Novo Nordisk
• Pfizer
• Quintiles
• Ranbaxy
• Roche
• Roche-Shanghai
• Sandoz
• Sanofi-Aventis
• Sanofi-Syn.M-Sheng
• Sansar Capital Management
• Sh.Asia Pioneer Pharma
• Shadong XINHUA Pharma
• Shandong Luoxin Pharma
• Shandong Qilu Fty
• Shanghai-Squibb
• Shenyang Sunshine Pharma
• Shenzhen Kexing Biotech
• Shenzhen Xinlitai
• Shijiazhuang Pharma Group
• Sichuan Kelun Pharma
• Sinovac Biotech
• Teva
• Th.James-Andy
• Tianjin Hualida Biotechnology
• Tianjin Smith Kline & Beecham
• Warburg Pincus
• Weisheng Pharmaceutical (Shijiazhuang) Co
• WuXi PharmaTech
• Wyeth
• Xiamen Amoytop Biotech
• Xian Janssen
• Xiangxue Pharmaceuticals
• Zhejiang Medicine
• Zhejiang NHU